Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases

J Hepatol. 1999 Jun;30(6):1028-34. doi: 10.1016/s0168-8278(99)80256-6.

Abstract

Background/aims: A recently identified DNA virus, termed TT virus (TTV), has been associated with post-transfusional hepatitis, and a high prevalence of TTV infection in patients with acute or chronic liver disease of unknown etiology has been reported from Japan, but few data are available about TTV infection in other countries.

Methods: Using hemi-nested-PCR amplification to detect TTV-DNA sequences in serum, we investigated TTV infection in blood donors and in patients with liver diseases of varied etiology.

Results: The prevalence of TTV infection was 13.7% in blood donors (23/168), 18.6% in chronic hepatitis C (19/102), 28.6% in chronic hepatitis B (16/56), 29.9% in hepatocellular carcinoma (20/67), 9.1% in cryptogenic chronic liver disease (2/22) and 39.6% in fulminant hepatitis (19/48). The prevalence of TTV infection in patients with virus-induced or idiopathic fulminant hepatitis was similar. Comparison of TTV-infected and non-infected patients did not reveal significant differences concerning demographic, epidemiological or histopathological features. In patients with hepatitis C, response to interferon therapy was not related to TTV infection. Phylogenetic analysis of TTV isolates showed that at least three different types of TTV are present in Spain.

Conclusions: Our data suggest that TTV infection is frequent among blood donors and patients with acute liver disease. However, pathogenic effects associated with TTV infection were not observed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Base Sequence
  • Blood Donors
  • Chronic Disease
  • DNA Viruses / pathogenicity*
  • Female
  • Hepatic Encephalopathy / virology
  • Hepatitis B, Chronic / virology
  • Hepatitis C, Chronic / therapy
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferons / therapeutic use
  • Liver Diseases / virology*
  • Male
  • Middle Aged
  • Prevalence

Substances

  • Interferons